SiBone (NASDAQ:SIBN) Given New $26.00 Price Target at UBS Group

Key Points

• UBS Group raised SiBone’s price target to $26 from $25 and maintained a “buy” rating, implying 12.44% upside from the prior close.
• SiBone reported a quarterly loss of $0.08 per share, beating the $0.13 consensus estimate, while revenue of $55.7 million slightly exceeded expectations. Analysts hold a consensus “Moderate Buy” rating with an average price target of $25.
• Shares rose to $23.12, near the company’s 52-week high, amid improving operating performance and strong institutional ownership; however, insiders sold approximately $4.7 million of stock over the past three months.

SiBone (NASDAQ:SIBN - Get Free Report) had its target price raised by stock analysts at UBS Group from $25.00 to $26.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's target price would indicate a potential upside of 12.44% from the stock's previous close.

Other research analysts have also recently issued reports about the stock. TD Cowen increased their price target on shares of SiBone from $20.00 to $23.00 and gave the company a "buy" rating in a report on Tuesday. Needham & Company LLC reduced their price objective on SiBone from $27.00 to $26.00 and set a "buy" rating for the company in a report on Tuesday. Truist Financial upped their target price on SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, October 14th. Weiss Ratings upgraded SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 20th. Finally, Citigroup reiterated a "market outperform" rating on shares of SiBone in a research note on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.00.

SiBone Stock Performance

Shares of SIBN traded up $2.90 during trading hours on Tuesday, hitting $23.12. The company had a trading volume of 736,082 shares, compared to its average volume of 616,200. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -68.66 and a beta of 0.66. The business has a fifty day moving average of $19.42 and a 200-day moving average of $16.45. SiBone has a 12 month low of $11.48 and a 12 month high of $22.95. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The company had revenue of $55.70 million during the quarter, compared to analysts' expectations of $55.31 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. Equities analysts anticipate that SiBone will post -0.40 EPS for the current fiscal year.

Insider Buying and Selling at SiBone

In related news, insider Anshul Maheshwari sold 3,738 shares of the business's stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $22.50, for a total value of $84,105.00. Following the completion of the sale, the insider directly owned 214,497 shares in the company, valued at approximately $4,826,182.50. The trade was a 1.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael Pisetsky sold 29,665 shares of the business's stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $22.11, for a total value of $655,893.15. Following the completion of the sale, the senior vice president owned 164,444 shares of the company's stock, valued at approximately $3,635,856.84. This trade represents a 15.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 238,371 shares of company stock valued at $4,738,916 in the last three months. Corporate insiders own 4.00% of the company's stock.

Institutional Trading of SiBone

A number of institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC grew its stake in SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock worth $132,649,000 after buying an additional 2,774,795 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after buying an additional 182,465 shares during the period. Renaissance Technologies LLC raised its position in shares of SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after buying an additional 238,219 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of SiBone by 40.3% in the 2nd quarter. Squarepoint Ops LLC now owns 118,128 shares of the company's stock valued at $1,928,000 after buying an additional 33,947 shares in the last quarter. Finally, Granahan Investment Management LLC raised its position in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock valued at $21,965,000 after buying an additional 858,942 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

Key Stories Impacting SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly loss and revenue beat expectations. SiBone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 analyst consensus, while revenue rose 14.5% year over year to $55.7 million, slightly ahead of the $55.3 million estimate. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Operating performance and cash generation improved. Adjusted EBITDA increased 32.4% to $3.0 million, operating cash flow jumped 154.4% to $5.9 million, and SiBone ended the quarter with $146.3 million in cash. These results strengthen the investment case despite continued GAAP losses. SI-BONE Reports Third-Quarter 2026 Results
• Positive Sentiment: Growth catalysts remain intact. U.S. procedure volume rose approximately 20%, the active physician base grew 16% to 1,770, and the company received FDA clearance for its iFuse Granite Onyx breakthrough device. New reimbursement rules could also increase hospital payments by as much as $50,000 for qualifying complex spinal-fusion procedures. SI-BONE Reports Third-Quarter 2026 Results
• Positive Sentiment: TD Cowen raised its price target. The firm lifted its target from $20 to $23 and maintained a “buy” rating, reinforcing bullish analyst sentiment as the stock approaches that revised objective. TD Cowen Analyst Rating
• Neutral Sentiment: Revenue guidance was reaffirmed. SiBone expects fiscal 2026 revenue of $231 million to $233 million, broadly in line with the $232.2 million consensus estimate. The outlook supports stability but does not represent a major forecast upgrade.
• Negative Sentiment: Insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for approximately $655,893, while Anshul Maheshwari sold 3,738 shares for $84,105. Both retained sizable positions, but the sales may modestly weigh on sentiment with SIBN near its 52-week high. Insider Sale Filing

SiBone Company Profile

SI-BONE, Inc NASDAQ: SIBN is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.